Suvorexant
- Generic Name
- Suvorexant
- Brand Names
- Belsomra
- Drug Type
- Small Molecule
- Chemical Formula
- C23H23ClN6O2
- CAS Number
- 1030377-33-3
- Unique Ingredient Identifier
- 081L192FO9
- Background
Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.
- Indication
Suvorexant is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
- Associated Conditions
- Insomnia
- Associated Therapies
- -
A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem
- Conditions
- Interventions
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 127
- Registration Number
- NCT05106153
- Locations
- ๐บ๐ธ
Altasciences Inc., Overland Park, Kansas, United States
Efficacy of Suvorexant in Patients With Effectively Treated Restless Legs Syndrome and Persistent Chronic Insomnia
- Conditions
- Interventions
- First Posted Date
- 2021-01-12
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 46
- Registration Number
- NCT04706091
- Locations
- ๐บ๐ธ
Massachusetts General Hospital, Boston, Massachusetts, United States
Efficacy and Safety of Suvorexant (MK-4305) for Reducing Incidence of Delirium in Japanese Participants at High Risk of Delirium (MK-4305-085)
- First Posted Date
- 2020-10-01
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 207
- Registration Number
- NCT04571944
- Locations
- ๐ฏ๐ต
Kanazawa Medical University Hospital ( Site 8514), Kahoku-gun, Ishikawa, Japan
๐ฏ๐ตNippon Medical School Musashi Kosugi Hospital ( Site 8502), Kawasaki, Kanagawa, Japan
๐ฏ๐ตTonan Hospital ( Site 8512), Sapporo, Hokkaido, Japan
Examining the Role of the Orexin System in Sleep and Stress in Persons With Opioid Use Disorder
- Conditions
- Interventions
- First Posted Date
- 2020-02-27
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 200
- Registration Number
- NCT04287062
- Locations
- ๐บ๐ธ
Behavioral Pharmacology Research Unit at the Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
๐บ๐ธAshley Addiction Treatment, Elkton, Maryland, United States
๐บ๐ธMan Alive Inc., Lane Treatment Center, Baltimore, Maryland, United States
Dual-Orexin Antagonism as a Mechanism for Improving Sleep and Drug Abstinence in Opioid Use Disorder
- Conditions
- Interventions
- First Posted Date
- 2020-02-10
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Wayne State University
- Target Recruit Count
- 120
- Registration Number
- NCT04262193
- Locations
- ๐บ๐ธ
Wayne State University, Detroit, Michigan, United States
Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP)
- Conditions
- Interventions
- First Posted Date
- 2019-07-10
- Last Posted Date
- 2023-10-27
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 60
- Registration Number
- NCT04014387
- Locations
- ๐บ๐ธ
University of California- San Francisco, San Francisco, California, United States
Suvorexant and Cocaine
- Conditions
- Interventions
- First Posted Date
- 2019-05-06
- Last Posted Date
- 2023-02-09
- Lead Sponsor
- William Stoops
- Target Recruit Count
- 8
- Registration Number
- NCT03937986
- Locations
- ๐บ๐ธ
University of Kentucky, Lexington, Kentucky, United States
Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2019-01-28
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 108
- Registration Number
- NCT03818581
- Locations
- ๐บ๐ธ
Massachusetts General Hospital, Boston, Massachusetts, United States
Impact of Suvorexant on Sympathetic Nerve Activity and Baroreflex Function in Chronic Insomnia
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2021-10-07
- Lead Sponsor
- Montana State University
- Target Recruit Count
- 34
- Registration Number
- NCT03768713
- Locations
- ๐บ๐ธ
Montana State University, Bozeman, Montana, United States
Treatment of Restless Legs Syndrome With the Hypocretin Antagonist Suvorexant
- First Posted Date
- 2018-11-27
- Last Posted Date
- 2018-11-29
- Lead Sponsor
- Diego Garcรญa-Borreguero, MD, PhD
- Target Recruit Count
- 43
- Registration Number
- NCT03755310
- Locations
- ๐ช๐ธ
Sleep Research Institute; Paseo de la Habana 151, Madrid, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.